Immune evasion in acute myeloid leukemia: current concepts and future directions by Ryan M Teague & Justin Kline
Teague and Kline Journal for ImmunoTherapy of Cancer 2013, 1:13
http://www.immunotherapyofcancer.org/content/1/1/13REVIEW Open AccessImmune evasion in acute myeloid leukemia:
current concepts and future directions
Ryan M Teague1*† and Justin Kline2,3*†Abstract
Immune responses generated against malignant cells have the potential to inhibit tumor growth, or even eliminate
transformed cells before a tumor forms. However, immune tolerance mechanisms that normally protect healthy
tissues from autoimmune damage pose a formidable barrier to the development of effective anti-tumor immunity.
Because malignant cells are derived from self-tissues, the majority of defined tumor antigens are either shared or
aberrantly expressed self-proteins. Eliciting productive T cell responses against such proteins is challenging, as most
high-affinity, self-reactive T cells are purged during thymic selection. Some T cells capable of tumor antigen
recognition escape thymic deletion, but are functionally inhibited by peripheral tolerance mechanisms which limit
their ability to attack a developing malignancy. Alternatively, some tumors express antigens derived from mutated
self-proteins, viral proteins or self proteins expressed only during embryonic development. These antigens are
recognized by the immune system as foreign and could be recognized by a relatively large number of peripheral
T cells. Even in this scenario, tumors evade otherwise effective T cell responses by employing potent
immunosuppressive mechanisms within their local environment. In the setting for solid malignancies, such as
melanoma, a growing number of putative immune evasion mechanisms have been characterized. However, acute
myeloid leukemia (AML) is a systemic disease, and the pathways it exploits to subvert the host immune response
may be quite different than those of a solid tumor. Much remains unknown regarding the immune escape
mechanisms promoted by AML, and whether efforts to thwart tolerance may influence the progression of this
disease. Here, we review current concepts of immune evasion in AML, and speculate how potentially effective
immunotherapeutic strategies might be developed to reverse immune tolerance in leukemia patients in the future.
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Acute myeloid leukemia (AML) is the most common
acute leukemia in adults. Treatment with modern chemo-
therapy regimens often induces complete remission, but a
majority of patients will ultimately relapse and succumb to
the disease. For many years it has been recognized that
allogeneic stem cell transplantation can be curative for
some patients with AML [1]. The major therapeutic effect
of allogeneic stem cell transplantation is derived from the
so-called graft-versus-leukemia effect thought to result* Correspondence: rteague@slu.edu; jkline@medicine.bsd.uchicago.edu
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distribution, and reproduction in any mediumfrom recognition of minor histocompatibility antigens
expressed on malignant cells in the host by donor-derived
T cells [2-5]. The existence of a graft-versus-leukemia ef-
fect has been further supported by evidence that infusions
of donor lymphocytes can induce disease remission in pa-
tients who have relapsed following allogeneic stem cell
transplantation [6]. Unfortunately, only a minority of pa-
tients with AML are candidates for this procedure. There-
fore, cancer immunologists have sought approaches to
stimulate anti-leukemia immunity within the host to pro-
mote immune-mediated elimination of AML.
In order to exploit the immune system to eradicate
leukemia cells, it is imperative to identify leukemia-specific
antigens that could be targeted, for example, through vac-
cination or adoptive cell therapy. Over the past decade, a
growing number of AML peptide antigens have been dis-
covered, including those derived from Wilm’s tumorntral Ltd. This is an Open Access article distributed under the terms of the
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ronan acid-mediated motility (RHAMM), and others [7].
Many of these antigens are over-expressed, but not
uniquely expressed by AML cells, and are thus classified
as tumor-associated antigens (TAA). Tumor-specific anti-
gens (TSA) uniquely expressed by AML cells have not
been characterized. Although AML cells express antigens
recognizable to host T cells, established leukemia is rarely
eradicated by the host immune system. One contributing
factor is that AML-derived antigens are also expressed in
other tissues, including the thymus. Thus, T cells in the
periphery capable of recognizing these antigens do so with
low avidity and are only able to elicit a weak immune re-
sponse upon encountering antigen-expressing AML cells
in vivo. Secondly, malignancies including AML employ a
number of immune evasion mechanisms which inhibit the
generation or functional execution of anti-tumor immune
responses. Over the past 15 years, a number of putative
tumor escape mechanisms have been identified, largely in
the setting of solid malignancies such as melanoma. They
include: establishment of a metabolically hostile micro-
environment [8,9], poor T cell costimulation by tumor
cells leading to T cell anergy [10], expression of negative
costimulatory ligands such as PD-L1 and Gal-9 within the
tumor environment [11,12], production of immune sup-
pressive cytokines and enzymes [13,14], expansion and/or
induction of suppressive cell types (regulatory T cells
(Tregs), myeloid-derived suppressor cells (MDSC) and
macrophages) [15,16]. Many of these pathways are acti-
vated in concert in the cancer-bearing host, thereby gener-
ating a network of interactions which are inhibitory to T
cell function and provide a permissive environment for
tumor progression.
The local environment created by AML cells to pro-
mote their survival and prevent their rejection by the
host immune system has been relatively under-explored.
Because AML is a systemic disease at its inception, it
seems reasonable to speculate that the mechanisms
which regulate immune activation versus tolerance in
the leukemia-bearing host may be quite different than
those in a host with a solid malignancy. In this review,
we will focus on what is currently known about immune
evasion in AML, considering data from pre-clinical
models, as well as from AML patients. Additionally, we
will speculate how these pathways may be interfered
with to enhance the efficacy of immunotherapeutic ap-
proaches for AML patients in the future.
Review
Putative mechanisms of cancer immune evasion
Tumor infiltrating lymphocytes (TIL) are present in many
human cancers. Among TIL are tumor antigen-specific T
cells which should theoretically be able to recognize and
eliminate antigen-expressing tumor cells. However, evenwhen heavily infiltrated by immune cells, malignancies
often continue to progress, suggesting that the tumor
environment actively inhibits the execution of anti-
tumor immune responses. In rapidly progressing can-
cers, the by-products of metabolism can impair T cell
function indirectly by generating hypoxic and acidic
conditions [8,9]. A number of additional immune eva-
sion mechanisms exploited by tumors are specifically
tailored to subvert T cell immunity, and are discussed
here with a focus on their role in promoting immune
escape by AML.
Circumventing immune surveillance
CD8+ and CD4+ T cells continuously survey antigenic
peptides presented by major histocompatibility complex
class I (MHC-I) and MHC-II molecules, respectively. Lost
or reduced expression of MHC molecules by cancer cells
has long been appreciated as a major impediment to the
ability of T cells to “see” and subsequently eliminate malig-
nant cells [17]. Diminished MHC expression on malignant
cells may occur due to mutations in the cellular machinery
necessary to present peptide/MHC on the cell surface
[18], or because of immunoediting by T cells that select-
ively kill tumor cells expressing higher concentrations of
antigen/MHC-I and leave behind those not so easily rec-
ognized [19]. Outgrowth of these antigen-loss variants is
much harder to contain by immunological means [20,21].
Loss of antigen/MHC-I has been described in a wide
range of human cancers [18], including relapsing AML
[20,21]. For example, Vago et al. studied 17 AML patients
who relapsed following haploidentical stem cell trans-
plantation and infusion of donor-derived T cells. AML
cells from 5 of these patients had lost expression of the
HLA haplotype which differed from that of the donor-
derived cells through the process of uniparental disomy of
chromosome 6p. Donor T cells were unable to recognize
and kill AML cells procured at the point of relapse because
they no longer expressed the restricting HLA molecules re-
quired for T cell recognition. This fascinating study pro-
vided evidence that AML cells can evade the host immune
response through immunoediting; a potentially critical bar-
rier to maintaining the graft-versus-leukemia response fol-
lowing allogeneic stem cell transplantation, and possibly
following other immune-based therapies.
Exploiting negative regulatory receptors
Negative regulatory receptors on T cells initiate intracellular
signaling events that interrupt activation cascades following
antigen recognition and costimulation. This naturally limits
T cell-mediated damage to self-tissues by modulating T cell
responses once invading pathogens are cleared, but also
presents a major obstacle to eliciting durable anti-tumor
immunity. For example, tumor cells can engage these path-
ways within T cells by up-regulating inhibitory ligands
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gands by tumor cells results from local IFNγ secretion by
activated TIL, revealing a remarkable adaptation by which
tumors can hijack an otherwise protective immune re-
sponse. Thus, it is not surprising that several regulatory re-
ceptors have become targets for cancer immunotherapy.
The most extensively studied negative regulatory recep-
tors are members of the CD28 family, and include cyto-
toxic T lymphocyte antigen-4 (CTLA-4) and programmed
cell death-1 (PD-1), which bind distinct members of the
B7 family of ligands. CTLA-4 is expressed on activated T
cells, as well as regulatory T cells, and binds to the ligands
B7.1 (CD80) and B7.2 (CD86) on antigen presenting cells
(APC). CTLA-4-deficient mice develop a rapidly lethal T
cell-mediated autoimmunity [24], which clearly demon-
strates the importance of CTLA-4 in down-regulating T
cell activation. On effector T cells, CTLA-4 has a much
higher affinity for B7 molecules, and is able to “outcom-
pete” CD28 for access to the immune synapse, thereby
limiting costimulation. Furthermore, CTLA-4 engagement
of B7 ligands diminishes APC function by modulating B7
expression and function in these cells. [25]. Blockade of
CTLA-4 enhances tumor immunity in animal models of
cancer, which is thought to rely on the enhancement of ef-
fector T cell activity, and the inhibition or deletion of regu-
latory T cells [26-28]. The potential of CTLA-4 blockade
to mobilize anti-tumor immunity has been recapitulated
in clinical trials for human melanoma and other solid tu-
mors [29-31], and in 2011 a monoclonal anti-CTLA-4
antibody (Ipilimumab) received FDA approval for the
treatment of patients with advanced melanoma.
Data supporting a significant negative regulatory role of
CTLA-4 in AML are limited. LaBelle et al. demonstrated
in a pre-clinical AML model that CTLA-4 blockade had
no significant impact on disease progression unless
leukemia cells were engineered to express B7 molecules
[32]. On the other hand, CTLA-4 blockade resulted in a
significantly enhanced expansion of functional human
AML-specific T cells cultured with autologous AML cells
[33]. Based on the favorable experience of CTLA-4 block-
ade in human solid tumors, it is now being evaluated
in clinical trials of patients with AML in relapse
(NCT01757639) or following allogeneic stem cell trans-
plantation (NCT01822509; NCT00060372).
PD-1 (CD279) is a receptor expressed on the surface of
activated T cells, B cells, and NK cells which binds to ei-
ther its broadly expressed tissue ligand PD-L1 (B7-H1/
CD274) or to its hematopoietically-restricted ligand PD-
L2 (B7-DC/CD273) [34,35]. PD-1 is commonly expressed
on T cells in the solid tumor environment, and a wide
variety of malignant cells (including AML cells) express
PD-L1. The expression of PD-1 on T cells and PD-L1 on
malignant cells impacts negatively on clinical outcome in
several cancer subtypes [11,36,37]. These early observationsprovided strong rationale for targeted blockade of PD-1/
PD-L1 interactions first in pre-clinical cancer models and
ultimately in humans with cancer.
As with CTLA-4, PD-1-deficient mice also develop auto-
immunity, but the disease is less severe and occurs later in
life [38]. The cytoplasmic tail of PD-1 contains a signaling
motif that when phosphorylated during ligation recruits
SHP phosphatases and disrupts CD28 and TCR signaling
cascades, specifically targeting the PI3K and Akt pathways
[39]. Studies in animal models have convincingly shown
that blockade of the PD-1 pathway can boost T cell im-
mune responses in solid tumors as well as in AML. Zhang
and colleagues demonstrated that leukemia antigen-
specific T cell responses and survival following AML in-
duction were significantly superior in PD-1-deficient mice,
and also in wildtype mice following administration of anti-
PD-L1 blocking antibodies [40]. Likewise, PD-1 and PD-L1
blockade have produced exciting results in patients with a
range of different solid cancers [41,42], and PD-1 blockade
is now being investigated clinically in AML patients in
combination with a dendritic cell-based cancer vaccine
(NCT01096602). It is also interesting to speculate that the
use of checkpoint blocking antibodies to stimulate a graft-
versus-leukemia effect following allogeneic stem cell trans-
plantation may be an efficacious strategy. However, due to
the non-antigen-specific T cell stimulatory capability of
these agents, it is also possible that they may also promote
graft-versus-host disease. Currently, there are several stud-
ies of CTLA-4 blockade in patients who have either
relapsed or who have persistent leukemia following alloge-
neic stem cell transplant (NCT00060372, NCT01822509),
though to our knowledge, PD-1 blockade in the post-
transplant setting has not yet been tested in humans.
Additional non-CD28/B7 family receptors such as
lymphocyte-activation gene-3 (LAG-3) and T cell im-
munoglobulin domain and mucin domain 3 (TIM-3) have
been identified as potential targets in cancer [43]. LAG-3
is a CD4-like molecule that binds to MHC-II with high af-
finity, and is primarily expressed on NK cells, γδ T cells,
Tregs and activated αβ T cells [44,45]. The mechanisms by
which LAG-3 regulates immune responses are not yet
completely understood. When expressed on activated or
exhausted T cells, LAG-3 acts as an inhibitory receptor
that requires the activity of a KIEELE motif in the cyto-
plasmic tail [46]. Preclinical studies have shown that dis-
ruption of the LAG-3 pathway can be achieved by
antibody blockade or genetic ablation to restore T cell re-
sponses against tumors. LAG-3 blockade is especially po-
tent when combined with PD-1 pathway inhibition
[47-51]. However, LAG-3 is also expressed on Tregs,
where it engages MHC-II on APC and inhibits their ability
to elicit effector T cell responses [52].
Clinically, LAG-3 blockade has been exploited by
administering a soluble form of the receptor (IMP321)
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NCT00354861) or those with different cancers inclu-
ding melanoma, breast cancer, renal cell carcinoma,
and pancreatic cancer (NCT01308294, NCT00349934,
NCT00351949, NCT00732082), but has not been tested
in AML patients to our knowledge. This clinical-grade
soluble LAG-3 is reported to target and activate a subset
of dendritic cells through ligation of MHC-II [53,54],
which seems contradictory to the role of LAG-3 on
Tregs. It is possible that IMP321 directly influences
APC, Tregs and effector T cells simultaneously to en-
hance immunity, but this has yet to be demonstrated
experimentally.
TIM-3 is an inducible negative regulatory receptor on T
cells that binds the ligand Galectin-9 [55]. Identified early
on as a marker of dysfunctional T cells in HIV patients
[56], TIM-3 expression has more recently been observed
on dysfunctional T cells within the solid tumor environ-
ment in pre-clinical models and from primary human
melanomas [12,57]. Combined TIM-3 and PD-1 expres-
sion on TIL identifies a particularly “exhausted” T cell
population [12,57]. TIM-3 blocking antibodies result in
enhanced anti-tumor T cell responses and control of
tumor growth in murine solid cancer models, especially
when combined with PD-1 and CTLA-4-blocking anti-
bodies [12,58,59]. In pre-clinical AML models, TIM-3-ex-
pressing T cells demonstrated a reduced ability to produce
effector cytokines, and typically co-expressed PD-1 [60].
Blockade of TIM-3 yielded a modest effect on survival fol-
lowing AML induction, while combined TIM-3 and PD-
L1 blockade demonstrated a synergistic effect [60]. Col-
lectively, these data suggest that TIM-3 blockade may also
be effective in re-awakening T cell responses in cancer pa-
tients, including those with AML, particularly in combin-
ation with anti-PD-1 or anti-CTLA-4 therapy.
Initial clinical trials testing the efficacy of so-called
“checkpoint blockade” with single agents, such as CLTA-4,
PD-1 or PD-L1 blocking antibodies have clearly demon-
strated their potential to augment immune responses
against a range of human cancers, but have also revealed a
limited benefit of monotherapy for the majority of treated
patients [29,41,42,61]. An emerging strategy to further im-
prove anti-tumor immunity in cancer patients is through
combinatorial blockade of negative regulatory receptors
on T cells. This approach is supported by results from ex-
periments in pre-clinical cancer models (including AML
models), in which combined checkpoint blockade was syn-
ergistic with regard to promoting enhanced anti-tumor T
cell responses and also improved control of tumor pro-
gression [12,47,49,60,62]. This effect is based on the idea
that simultaneous blockade of several non-redundant
negative regulatory pathways is likely to maximally re-
engage multiple T cell functions for optimal anti-tumor
immunity. For example, PD-1 and CTLA-4 blockade wasrecently shown to prevent the deletion of tumor-reactive
T cells, whereas additional blockade of LAG-3 was vital to
promote greater effector function among these persisting
TIL – providing a clear survival benefit for leukemia-
bearing hosts [47]. Several clinical trials are now underway
to evaluate safety and efficacy of combined PD-1 and
CTLA-4 blockade in patients with renal cell carcinoma,
non-small cell lung cancer, or melanoma (NCT01783938,
NCT01472081, NCT01454102, NCT01024231). However,
in light of the potentially life-threatening autoimmune
complications which can occur with single-agent CTLA-4,
PD-1 and PD-L1 antibody blockade, [29,31,41,42,63], cau-
tion will be needed when combining these agents. It is
tempting to speculate that optimal combinations may
allow for lower doses of individual antibodies, thereby re-
ducing potential toxicity to healthy tissues while main-
taining robust anti-tumor immunity. Indeed, one human
trial has recently reported that concurrent blockade of
CTLA-4 and PD-1 was synergistic in generating anti-
tumor responses in melanoma patients, while adverse
immune-related toxicities were no more prevalent than
with monotherapy [64]. There are presently no clinical tri-
als to our knowledge evaluating combined checkpoint
blockade in AML patients.Accumulating suppressor cell populations
Regulatory T cells (Tregs) are a naturally immunosuppres-
sive CD4+ T cell population defined by their expression of
the FoxP3 transcription factor, which is necessary for their
developmental and functional programs [65,66]. Loss of
function mutations in the FoxP3 locus result in severe
autoimmune complications in mice and humans, highlight-
ing the critical role of Tregs in the maintenance of periph-
eral tolerance to self-antigens [67,68]. Tregs can develop in
the thymus as “natural” Tregs, or be induced in the periph-
ery from conventional CD4+ T cells following exposure to
TGF-β or retinoic acid [69]. Treg-mediated suppression of
effector T cells is accomplished through diverse mecha-
nisms that include competition for IL-2 [70], secretion of
inhibitory cytokines, such as IL-10, IL-35 [71], and TGFβ
[72], production of extra-cellular adenosine [73], and by al-
tering the function of antigen presenting cells through their
engagement of CTLA-4 and LAG-3 expressed on Tregs
[52,74,75].
Tregs accumulate in the peripheral blood and within tu-
mors in a wide variety of malignancies. In many cases, the
density of tumor-associated Tregs correlates directly with
disease stage (i.e. tumor burden) [16]. Dozens of studies
have attempted to link the Treg frequency in the tumor
environment with clinical outcome [76], with varying re-
sults. However, a majority have indicated that a high Treg
density in the tumor tends to correlate unfavorably with
clinical outcome [77]. Whether Tregs play a causal role in
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be proven.
Reports of Treg accumulation in cancer-bearing pa-
tients inspired a host of pre-clinical studies to determine
whether Treg depletion would enhance anti-tumor im-
mune responses. In fact, inhibition or depletion of Tregs
in a number of transplantable cancer models resulted in
significantly enhanced anti-tumor T cell responses and
control of tumor progression [78-80]. In an attempt to
translate these exciting pre-clinical observations into
cancer patients, and taking advantage of the constitutive
expression of the IL-2 receptor α-chain by the majority
of Tregs, several groups have tested whether a fusion
protein of IL-2 and diphtheria toxin (denileukin diftitox)
could deplete Tregs in this setting. The results from these
experiments have been mixed. An early report from
Dannull and colleagues concluded that denileukin diftitox
significantly reduced Treg numbers in patients with meta-
static renal cell carcinoma which led to enhanced T cell
responses following vaccination [81]. Morse et al. also
found that denileukin diftitox depleted Tregs in cancer pa-
tients, but only following multiple administrations. Here
again, Treg depletion correlated with enhanced T cell re-
sponses raised following vaccination [82]. However, mul-
tiple studies have failed to repeat the early promising
results with this agent, and reported either no or a very
transient reduction in circulating Tregs following its ad-
ministration [83,84], which has tempered enthusiasm for
this strategy. More recently, effective and somewhat dur-
able Treg depletion has been demonstrated in cancer pa-
tients following administration of anti-CD25 monoclonal
antibodies (Daclizumab) [85-87]. Treg depletion led to en-
hanced adaptive immune responses raised following vac-
cination in 2 of 3 studies [86,87], while its administration
appeared to diminish functional antigen-specific T cell re-
sponses in another study, possibly because the anti-CD25
antibody also depleted activated T cells which can also ex-
press CD25 [85]. Overall, these studies suggest that Treg
depletion is achievable through anti-CD25 antibody ad-
ministration, but also that dose and schedule may be crit-
ical factors to consider.
In AML, several groups have observed elevated Treg
frequencies in the peripheral blood and bone marrow of
AML patients compared to controls [88-90]. In these
retrospective studies, Treg frequency in the peripheral
blood of AML patients appeared to correlate negatively
with response to induction chemotherapy and survival.
Tregs from AML patients are also more suppressive
in vitro than those from healthy controls [89]. In murine
AML models, Tregs accumulate in leukemia-bearing mice
[[91] and J. Kline unpublished observations], and their de-
pletion alone or in combination with PD-L1 blockade
resulted in enhanced anti-leukemia T cell responses
[91,92]. For these reasons Treg ablation or inhibitionremain attractive strategies to promote effective anti-
tumor immunity in humans with AML. Clinical studies
are now underway to investigate if T cell responses to
tumor vaccines are augmented in AML patients following
depletion of Tregs (NCT01513109; NCT01842139).
Over 25 years ago, populations of suppressive myeloid
cells were found to expand in cancer-bearing animals
[93]. These immature myeloid cells, now called myeloid-
derived suppressor cells (MDSC), are comprised of a
heterogeneous mixture of cells morphologically resem-
bling either monocytes or granulocytes [94]. In mice,
MDSC are characterized by the expression of CD11b
and Gr-1 [95], while in humans MDSC are described as
CD11b+CD14-CD33+ cells [96]. Present at very low fre-
quencies outside of the bone marrow in healthy individ-
uals, MDSC are capable of massive expansion in cancer
patients, where they potently inhibit the proliferation
and effector function of anti-tumor T cells through their
production of arginase, nitric oxide and reactive oxygen
species [15]. MDSC can also promote Treg induction
[97]. In pre-clinical cancer models, effective strategies
have been employed to either promote MDSC matur-
ation [98], modulate their function [99], or target them
for depletion [100,101]. Therapeutic targeting of MDSC
in humans with cancer has not been successfully accom-
plished to date. MDSC also expand in animal AML
models [102], but their role in suppressing the prolifera-
tion and function of leukemia antigen-specific T cells
has not been explored in mice or humans.Inhibitory enzymes
Indolamine 2,3-dioxygenase (IDO) is an enzyme which
catalyzes the rate-limiting step in tryptophan degradation
along the kynurenine pathway [103]. T cells are extremely
sensitive to environmental levels of tryptophan, and its
local depletion strongly inhibits T cell proliferation, while
tryptophan metabolites negatively regulate T cell activation
and survival [104]. IDO is expressed by hematopoietic
cells, such as plasmacytoid dendritic cells and immature
DC [105], and also by non-hematopoietic cells, including
bone marrow-derived mesenchymal cells [106]. A seminal
study implicated IDO in cancer immune evasion after
its expression was demonstrated in a wide variety of
human malignancies [14]. In a murine model, IDO-
expressing tumor cells grew progressively, while those
negative for IDO expression were rejected. Numbers of
tumor antigen-specific T cells were significantly lower
in mice with IDO-expressing tumors, suggesting that
IDO negatively regulated T cell proliferation. Following
administration of 1-methyltryptophan (1-MT), a com-
petitive inhibitor of IDO [107], IDO-expressing tumors
progressed much more slowly, and this effect was T
cell-dependent [14].
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et al. observed IDO expression among half (40 of 76) of
AML bone marrow samples tested [108]. Similar to
many solid tumors, IDO expression by AML cells
appeared to be constitutive, and was not upregulated by
IFN-γ, arguing that its expression by AML cells might
occur as part of the transformation process, supported
by the finding that normal CD34+ hematopoietic precur-
sor cells did not express the IDO protein. The enzymatic
activity of IDO is also enhanced in the blood of AML
patients compared to controls [109].
Expression of IDO by plasmacytoid dendritic cells in
tumor-draining lymph nodes negatively regulates T cell
function by activating suppressive pathways within mature
Tregs [110,111]. In a fascinating set of experiments, Curti
et al. identified increased circulating Treg frequencies in
leukemia patients whose AML cells expressed IDO [112].
IDO-expressing AML cells were able to induce FoxP3 ex-
pression in conventional CD4+CD25- T cells which devel-
oped suppressive capabilities in vitro. IDO inhibition
through 1-MT completely abrogated this effect. Collect-
ively, these observations support a model in which IDO
production, either by dendritic cells or by AML cells pro-
motes immune evasion by directly inhibiting proliferation
of tumor-specific T cells, or indirectly by promoting Treg
induction and/or suppressive capability.
Based on these data, and because IDO expression by
AML cells may result in poor clinical outcomes [109,113],
inhibition of IDO may be a promising approach to combat
immune evasion by AML. Recently, extremely potent IDO
inhibitors, such as INCB024360 (Incyte Corporation),
have been developed and appear to be highly active in
pre-clinical cancer models [114]. Several early-phase stud-
ies evaluating the efficacy of INCB024360 are ongoing in
solid malignancies (NCT01685255; NCT01604889), and
in myelodysplastic syndrome (NCT01822691), a disease
that often progresses to AML.
Deletional T cell tolerance
Our laboratory has recently uncovered a previously
undescribed mechanism of peripheral tolerance which
occurs quite rapidly in hosts harboring AML [102].
Using the C1498 AML model, we explored leukemia-
antigen specific T cell responses to AML cells inoculated
either subcutaneously (to mimic a solid tumor) or intra-
venously (to model a leukemia). While functional T cell
responses against subcutaneously-inoculated AML cells
were vigorous, those generated following intravenous
AML cell inoculation were quite poor. Interestingly, an
intravenous challenge with AML cells prevented T cell
activation following a subsequent subcutaneous AML
cell challenge in the same animal, suggesting that the
systemic presence of AML cells actively promoted per-
ipheral T cell tolerance. T cell receptor transgenic T cellsspecific for our model tumor antigen underwent abortive
proliferation in hosts following a systemic AML cell chal-
lenge. Over-expression of the anti-apoptotic Bcl-XL pro-
tein in leukemia antigen-specific T cells completely
restored their ability to accumulate in hosts with AML,
confirming T cell deletion as a mechanism of potent per-
ipheral tolerance in AML. Deletional T cell tolerance in
this model could be reversed following administration of
an agonistic anti-CD40 antibody to systemically activate
host DCs, which not only significantly enhanced antigen-
specific T cell responses in mice harboring AML cells sys-
temically, but also improved their survival. These findings
are important not only because we have identified a
unique mechanism of immune evasion in AML, but also
because they demonstrate a sharp contrast between how
the immune system recognizes and is regulated by solid
and hematological malignancies.
Conclusions
Based on the discussion above, it should be clear that
the tumor environment is well-equipped to subvert the
host immune response generated against it. An emerging
consensus is that future immunotherapies are likely to
benefit from efforts to thwart tumor immune evasion.
The evasion mechanisms employed by AML have only
recently begun to be clarified, generating the next layer
of fundamental questions for further investigation. For
example, 1) What are the relative contributions of indi-
vidual immune escape pathways in AML patients? 2)
Does AML utilize immune evasion mechanisms that are
yet to be discovered? 3) Do specific subtypes of AML
differentially employ unique combinations of immune
escape mechanisms? 4) How can strategies to reverse
immune evasion be effectively coupled with standard
immunotherapy approaches? 5) At what stage in the dis-
ease process should immune-based therapies (including
strategies aimed at the reversal of immune evasion path-
ways) be delivered in order to maximize efficacy?
In this review, we have discussed the major immune
evasion mechanisms with particular relevance to AML.
Because AML is a systemic disease at its inception, the
environment it creates is likely dissimilar in many as-
pects from anatomically-localized solid malignancies.
Therefore, it seems reasonable to speculate that the im-
mune evasion mechanisms employed in AML may differ
from those in solid tumors. On the other hand, there is
clear overlap in several immune escape pathways pro-
moted by AML and solid tumors, such as expansion of
Tregs, expression of negative regulatory receptors, pro-
duction of IDO and lack of T cell costimulation. Truly
unique immune tolerance mechanisms employed in
AML have not been described, although our laboratory
has recently characterized a deletional T cell tolerance
mechanism in AML that that does not appear to be
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for leukemia-derived antigens were deleted, likely
through interactions with immature host dendritic cells
which cross-presented leukemia antigens in a context
unfavorable to T cell activation, resulting in abortive T
cell proliferation and dysfunctional cytokine production.
It is reasonable to predict that additional mechanisms of
T cell tolerance in AML will continue to be uncovered.
Additionally, as distinct AML subtypes are further char-
acterized in patients (i.e. core binding factor, FLT-3-mu-
tated and Ras-mutated AML), it will be interesting to
compare the immune escape pathways employed in
these cohorts. If genetically similar AMLs reliably are
found to exploit a common network of immune evasion
mechanisms, it would provide strong rationale for devel-
oping clinical trials testing the reversal of specific im-
mune evasion pathways in groups of patients who would
be more likely to benefit.
Current immunotherapy strategies, such as vaccin-
ation and adoptive T cell transfer have historically not
been beneficial for a majority of patients. However, ani-
mal models in which vaccine or adoptive T cell therapy
have been combined with approaches to reverse im-
mune evasion have yielded quite promising results. As
discussed above, there are now several ongoing studies
testing such combinations in cancer patients. In AML,
our institution is coupling a WT1 peptide-based vaccine
with Treg depletion (using an anti-human CD25 anti-
body), and other groups are exploring similar approaches
(NCT01096602; NTC01513109). While the possible com-
binations to be explored are nearly endless, it is antici-
pated that as effective approaches to reverse immune
evasion in leukemia patients are identified, they will be
prioritized for study with standard immunotherapy.
Timing is a critical factor to consider when delivering
immunotherapy in cancer, and AML is likely no exception.
Clear evidence from animal models suggests that im-
munotherapy is less effective when administered to hosts
with high tumor burden because of the well-established
immune suppressive networks in larger tumors. In AML
for example, patients with large numbers of marrow and/
or peripheral blood blasts are certainly less likely to benefit
from immunotherapy than those who have achieved a
complete response. Because standard chemotherapy is ef-
fective at inducing complete remission in most AML pa-
tients (many of whom ultimately will relapse), there is
reason to speculate that immunotherapy will provide the
greatest benefit to patients in a minimal residual disease
(MRD) state.
In conclusion, immune evasion in AML represents a
major hurdle to the delivery of effective immunotherapy.
With the recent characterization of several putative im-
mune escape mechanisms in AML, opportunities to in-
hibit these pathways are becoming available. Emergingdata from patients with solid malignancies suggests that
circumventing these immunosuppressive pathways can
lead to impressive objective clinical responses. However,
there is much that remains to be explored both in the la-
boratory and in patients. In the future, we envision that
targeting the reversal of immune evasion in combination
with more classical immunotherapies, preferably deliv-
ered in the MRD state, may lead to the eventual incorp-
oration of effective immune-based therapies into current
treatment protocols to reduce the risk of AML relapse
and improve overall outcomes for patients.
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